Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute
Columbus, OH
Accepting patients
ELEMENT-MDS
Phase 3 Clinical Trial Comparing Luspatercept VS Epoetin Alfa in Patients with Very Low – Intermediate Risk MDS Who Are Not Transfusion Dependent
- Erythroid Maturation Agent (EMA)
- Erythropoiesis-Stimulating Agent (ESA)
- Red Blood Cell Stimulant
- Phase 3
Accepting patients
SGR-2921
A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- CDC7 Inhibitor
- Phase 1
Accepting patients
ACCESS
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
- Allogeneic Stem Cell Transplant
- Pre-Transplant
- Phase 2
Accepting patients
OPTIMIZE
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
BH-30236
A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- CLK Inhibitor
- Phase 1
Accepting patients
PyramIDH
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)
- IDH1 Inhibitor
- Randomization
- Phase 3
Accepting patients
TakeAim
TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- IRAK 4 Inhibitor
- Phase 1/2
- Has results
Accepting patients
Venetoclax and Azacitidine for Therapy-Related MDS
Phase II Study of Clinical Efficacy of Venetoclax in Combination With Azacitidine in Patients With Therapy Related Myelodysplastic Syndrome (t-MDS)
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 2
Accepting patients
ASTX030
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
- DNMT1 Inhibitor
- Phase 2/3
Accepting patients
LIMBER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
- BET Inhibitor
- JAK1 Inhibitor
- JAK2 Inhibitor
- Phase 1